Antonio Ojea

Suggest Changes

Writes About:

Learn More
BACKGROUND European Organization for Research and Treatment of Cancer (EORTC) risk tables only included 171 patients treated with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer(More)
BACKGROUND Bacillus Calmette-Guérin (BCG) maintenance therapy for 3 yr following BCG induction can reduce the progression of urothelial bladder carcinoma versus BCG induction alone, but is associated(More)
OBJECTIVE The primary aim was to search for lower doses of Bacillus Calmette-Guerin (BCG) that are effective and have lower toxicity. METHODS A low dose of BCG 27 mg was compared with BCG 13.5mg,(More)
Antonio Ojea *, José Luı́s Nogueira , Eduardo Solsona , Nicolás Flores , Jesús Marı́a Fernández Gómez , Jesús Rodrı́guez Molina , Venancio Chantada , José Emilio Camacho , Luı́s Martı́nez Piñeiro ,(More)
BACKGROUND Intravesical bacillus Calmette-Guérin (BCG) is an effective therapy in non-muscle-invasive bladder cancer (NMIBC), but it has limitations in terms of recurrence and toxicity. OBJECTIVE(More)